CRIP2 Inhibitors
Chemical inhibitors of CRIP2 can be identified based on their ability to target specific signaling pathways in which CRIP2 is known to be involved. Staurosporine, a protein kinase inhibitor, can inhibit CRIP2 activity by targeting the kinases that interact with CRIP2, thus disrupting the signal transduction processes. Similarly, kinase signaling pathways that involve CRIP2 can also be inhibited by PP2, which targets Src family kinases. This inhibition can result in the functional suppression of CRIP2. The involvement of CRIP2 in the MAPK/ERK pathway provides a basis for the use of U0126 and PD98059, both of which are MEK inhibitors. By inhibiting MEK, these chemicals can decrease the activity of the ERK pathway, therefore reducing the signaling activities associated with CRIP2.
Furthermore, CRIP2 function can be influenced by the inhibition of other pathways, such as the PI3K/AKT pathway and the JAK/STAT pathway. LY294002 and Wortmannin are PI3K inhibitors that can suppress AKT pathway signaling, which in turn can decrease CRIP2 activity. Rapamycin, an mTOR inhibitor, also targets the downstream components of the PI3K/AKT pathway, leading to a reduction in the pathway's activity and consequent diminishment of CRIP2 function. The JAK/STAT signaling pathway, which may involve CRIP2, can be inhibited by AG490, a JAK2 inhibitor, thus preventing the activation of STATs and the associated CRIP2 activity. Additionally, by targeting the p38 MAPK with SB203580, a p38 MAPK inhibitor, and the JNK pathway with SP600125, a JNK inhibitor, the MAPK pathway activity, which CRIP2 is part of, can be reduced. Lastly, CRIP2 activity can be influenced by the inhibition of receptor tyrosine kinases such as EGFR and FGFR, which can be achieved with the use of Gefitinib and PD173074, respectively.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. CRIP2 is a LIM domain-containing protein that may interact with kinases in signal transduction. Staurosporine can inhibit these kinases, thereby potentially inhibiting the signaling processes which involve CRIP2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3 kinase inhibitor; PI3K is a part of the AKT signaling pathway, which may be linked to CRIP2 function. Inhibition of PI3K by LY294002 can reduce AKT pathway signaling, potentially decreasing CRIP2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can reduce the activity of the MAPK/ERK pathway, thereby indirectly inhibiting the signaling processes involving CRIP2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. CRIP2 is linked with MAPK signaling, and by inhibiting JNK, SP600125 can suppress the JNK pathway activity, thus potentially inhibiting CRIP2 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, and since p38 MAPK is part of the MAPK pathway, which CRIP2 is associated with, inhibition of p38 MAPK by SB203580 could lead to decreased CRIP2 signaling activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, and by inhibiting PI3K, it can reduce AKT signaling. CRIP2 has been related to the AKT pathway, and inhibition of this pathway by Wortmannin might lead to a functional inhibition of CRIP2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR is a downstream effector in the PI3K/AKT pathway. By inhibiting mTOR, Rapamycin can decrease the activity of the PI3K/AKT pathway, which is relevant to CRIP2 function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases. CRIP2 may be involved with Src kinase signaling, and thus, inhibition of Src kinases by PP2 could lead to a reduction in CRIP2 activity. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
AG490 is a JAK2 inhibitor, and since CRIP2 has been related to JAK/STAT signaling, inhibition of JAK2 by AG490 can prevent the activation of the STATs, potentially leading to an inhibition of CRIP2 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor, and CRIP2 might be involved in EGFR signaling. By inhibiting EGFR, Gefitinib could decrease downstream signaling that involves CRIP2. | ||||||